A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Susan Mary O'Brien
Research Funding - Gilead Sciences
Nicole Lamanna
Research Funding - Gilead Sciences
Thomas J. Kipps
Research Funding - Gilead Sciences
Ian Flinn
Research Funding - Gilead Sciences
Andrew David Zelenetz
Research Funding - Gilead Sciences
Jan Andreas Burger
Research Funding - Gilead Sciences
Leanne Holes
Employment or Leadership Position - Gilead Sciences
David Michael Johnson
Employment or Leadership Position - Gilead Sciences
Jessie Gu
Employment or Leadership Position - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Ronald L. Dubowy
Employment or Leadership Position - Gilead Sciences
Steven E. Coutre
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences